Zim Laboratories (NSE:ZIMLAB) Other Long-Term Liabilities: ₹104 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
78 GF Score
Price ₹118.85
GF Value ₹102.66
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Other Long-Term Liabilities?

Zim Laboratories NSE:ZIMLAB +2.00% 78 Other Long-Term Liabilities is ₹104 Mil as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 78/100 and a GF Value™ of ₹102.66 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Zim Laboratories's other long-term liabilities for the quarter that ended in Mar. 2026 was ₹104 Mil.

Zim Laboratories's quarterly other long-term liabilities declined from Sep. 2025 (₹118 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹104 Mil).

Zim Laboratories's annual other long-term liabilities increased from Mar. 2024 (₹101 Mil) to Mar. 2025 (₹113 Mil) but then declined from Mar. 2025 (₹113 Mil) to Mar. 2026 (₹104 Mil).

Zim Laboratories Other Long-Term Liabilities Related Terms

Zim Laboratories Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Other Long-Term Liabilities Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.63 48.03 101.01 113.01 104.20

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.01 0.00 118.23 0.00 104.20
NSE:ZIMLAB
78GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹104 Mil mean?
Zim Laboratories (NSE:ZIMLAB) has a Other Long-Term Liabilities of ₹104 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zim Laboratories and its competitors.
Is Zim Laboratories' Other Long-Term Liabilities too high?
Zim Laboratories' current Other Long-Term Liabilities is ₹104 Mil. Overall, Zim Laboratories has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Other Long-Term Liabilities compare to ZTS and UTHR?
Zim Laboratories' Other Long-Term Liabilities of ₹104 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current Other Long-Term Liabilities is ₹104 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.66, compared to a current price of ₹118.85 — trading 15.8% above its estimated fair value. The current Other Long-Term Liabilities is ₹104 Mil. Zim Laboratories' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Other Long-Term Liabilities is ₹104 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹118.85 is trading 15.8% above its estimated GF Value™ of ₹102.66. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Other Long-Term Liabilities: ₹104 Mil
  • GF Value™: ₹102.66 vs. price of ₹118.85 (15.8% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
78GF Score

Get the complete analysis for NSE:ZIMLAB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹118.85
Price
₹102.66
GF Value